1. reagent in prostate cancer Mohammad Hossein Nasr Esfahani 1*
Fabrication and characterization of ZnO-Nanoparticules, using as siRNA delivery
reagent in prostate cancer
Mohammad-Hossein Beigi 1†, Farzad Seyed Forootan 1,2†, Navid Abedpour 1, Masoud Baghi 1, Iman Niktab 1,
Mohammad Hossein Nasr Esfahani 1*
†Authors with equal contribution.
1. Department of Cellular Biotechnology ,Cell Science Research Center, Royan Institute for Biotechnology, ACECR ,Isfahan ,Iran.
2. Department of molecular and clinical cancer medicine, Institute of translational medicine, University of Liverpool, Liverpool, UK.
Objectives
water to remove the byproducts. After washing, the ZnO nanoparticles were dried at 80℃ in hot air oven with constant stirring for 5 hours.The resultant powder was annealed at 500 ℃ for 5 hours. The final product ZnO nanoparticles were investigated by X-Ray Diffraction (XRD), Fourier-transform infrared spectroscopy (FT-IR), Scanning Electron Microscope (SEM),and Cell viability was measured after 3, 5 and 7 days using the MTS assay in PC3M cells-highly malignant prostate cancer cell lines (for minimum toxicity to healthy cells from ZnO without conjugated drug) respectively.
Great conflict in the treatment of prostate cancer tends to castration-resistant prostate cancer cases. Unfortunately, most of the patients experience some degree of androgen independency even after two years of starting routine treatments. Recent developments in personalized medicine in advanced cancer treatment, opened new windows in to survey whom struggling with prostate cancer, particularly castration-resistant patients. Nowadays, a great deal of attention directed towards specialized treatments which focus on interacting the genes whose activity tends to grow in cancer. Using siRNAs capable the scientists to manipulate the gene activity. Due to siRNA instability, its widespread use as systemic treatment in cancer patients, is still need more overview. On the other hand, for using the siRNAs as treatment reagents, must be ensured to be released only in the target tissues. The capability of nanoparticles in carrying and releasing drugs in target organs motivated the hypothesis in which siRNAs will be stabilized in conjunction with nanoparticles and then it would be expected to be gradually released in the target tissues. In the view of the fact that Metal concentration of zinc in prostate cells is times greater than in other body cells, applying zinc nanoparticles to carry and deliver drugs to the target tissue appears to be a reliable method.
FT-IR peak at cm-1 indicated characteristic bands OF ZnO nanoparticles.
Results
Results from recent study shows a typical XRD pattern of ZnO nanoparticles, the average crystal size of synthesized nanoparticles was calculated and FT-IR peak at cm-1 indicated characteristic absorption bands OF ZnO nanoparticles. The SEM image shows that ZnO nanoparticles prepared in this study are spherical in shape. Using MTS assay, it has been shown that PC3M cell viability were intact when treated ZnO with a concentration of 35 μg/ml. On the other hand, Forootan,et al studies revealed that delivering siRNAs by atelocollagen could reduce the prostate cancer progression in mice model.
Forootan,et al studies revealed that delivering siRNAs by atelocollagen could reduce the prostate cancer progression in mice model. (a) and weight (b) measured at the end of different treatments.
Key words
ZnO-Nanoparticules, cytotoxicity, siRNA delivery, prostate cancer.
References
Boyle, P.; Levin, B. World Cancer Report International Agency for Research on Cancer World Health Organization; 2009.
Mortimer M, Kasemets K, Kahru A. Toxicity of ZnO and CuO nanoparticles to ciliated protozoa Tetrahymena thermophila. Toxicology 2010;269:182–9.
Moos PJ, Chung K, Woessner D, et al. ZnO Particulate Matter Requires Cell Contact for Toxicity in Human Colon Cancer Cells. Chem Res Toxicol 2010;23:733–9.
SHIVA S. FOROOTAN, ZHENG Z. BAO, FARZAD S. FOROOTAN, LALEH KAMALIAN, YU ZHANG, ALIX BEE, CHRISTOPHER S. FOSTER and YOUQIANG KEAtelocollagen-delivered siRNA targeting the FABP5 gene as an experimental therapy for prostate cancer in mouse xenografts. INTERNATIONAL JOURNAL OF ONCOLOGY 36: 69-76, 2010
Conclusions
Methods
Up to the finding of this study we decided to make zinc nanoparticles and charge them with siRNA with the aim of applying them to cancerous cells. This study focused on fabrication and characterization ZnO-NPs for the biomedical applications and drug delivery to improve their targeting and cytotoxicity against cancer cells and minimum toxicity to healthy cells.
Zinc oxide nanoparticles were synthesized by sol-gel method using zinc acetate and methanol as precursors. In the preparation, 16 g of zinc acetate was dissolved in 112 ml of methanol. After 10 minutes magnetic stirring at room temperature. Nano zinc oxide was washed several times with double distilled